Targets for Anti-T. Cruzi Drugs in the Post-Genomic Era

Current Enzyme Inhibition

Volumn 6, Issue 4, 2010, Pages 195-210

  Merlino, Alicia ^a   González, Mercedes ^a,b   Cerecetto, Hugo ^a,b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Chagas'disease; Drugs development; Enzymatic inhibitors

Indexed keywords

2 DIFLUOROMETHYL 4 NITROPHENYL 3,5 DIDEOXY DEXTRO GLYCERO ALPHA DEXTRO GALACTO 2 NONULOPYRANOSID ACID; ANTHRAQUINONE DERIVATIVE; ANTITRYPANOSOMAL AGENT; BENZIMIDAZOLE; BENZNIDAZOLE; CYCLIC AMP PHOSPHODIESTERASE; DIPYRIDAMOLE; ETAZOLATE; GUANOSINE TRIPHOSPHATASE; HYDROXAMIC ACID DERIVATIVE; IMAZODAN; ISOQUINOLINE DERIVATIVE; MEVALONIC ACID; MILRINONE; N ACETYLNEURAMINIC ACID; NIFURTIMOX; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RISEDRONIC ACID; ROLIPRAM; THEOPHYLLINE; TIPIFARNIB; TREQUINSIN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

AMINO ACID SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; CHAGAS DISEASE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CRITHIDIA FASCICULATA; CRYPTOSPORIDIUM PARVUM; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INACTIVATION; IC 50; LEISHMANIA; NONHUMAN; PHARMACOPHORE; PROTEIN MOTIF; PROTEIN PRENYLATION; PROTEIN TARGETING; RNA INTERFERENCE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 79954445625     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340810794578533     Document Type: Article

References (130)

1. Chagas, C. Nova entidade morbida do homen. Resumo geral dos estudos etiológicos e clínicos. Mem. Inst. Oswaldo Cruz, 1911, 3, 219-275.
2. http://www.who.org/.
3. Schofield, C.J.; Dias, J.C. The Southern Cone initiative against Chagas disease. Adv. Parasitol., 1999, 42, 1-27.
4. Available at http://www.who.int/tdrold/publications/tdrnews/news63/chagas.htm (Accessed December 19, 2010).
5. Brum-Soares, L.M.; Salles Xavier, S.; Silvestre de Sousa, A.; Borges-Pereira, J.; Bemfica Barbosa Ferreira, J.M.; Ribeiro Costa, I.; Verissimo Junqueira, A.C.; Rodrigues Coura, J. Morbidity of Chagas disease among autochthonous patients from the Rio Negro microregion, State of Amazonas. Rev. Soc. Bras. Med. Trop., 2010, 43, 170-177.
6. Monteiro, W.M.; das Graças Vale Barbosa, M.; de Ornelas Toledo, M.J.; Fé, F.A.; Ferreira Fé, N. Series of acute Chagas' disease cases attended at a tertiary-level clinic in Manaus, State of Amazonas, from 1980 to 2006. Rev. Soc. Bras. Med. Trop., 2010, 43, 207-210.
7. Marques da Silva, E.; da Costa Rocha, M.O.; Silva, R.C.; do Carmo Paixão, G.; Buzzati, H.; Nogueira Santos, A.; do Carmo Pereira Nunes, M. Clinic and epidemiological study on Chagas disease in the Serra Azul district of Mateus Leme, central-western region of the State of Minas Gerais, Brazil. Rev. Soc. Bras. Med. Trop., 2010, 43, 178-181.
8. Bergmann Araújo, A.; Delpizzo Castagno, V.; Gallina, T.; Aires Berne, M.E. Prevalence of Chagas disease among pregnant women in the southern region of Rio Grande do Sul. Rev. Soc. Bras. Med. Trop., 2009, 42, 732-733.
9. Norman, F.F.; Pérez de Ayala, A.A.; Pérez-Molina, J.A.; Monge- Maillo, B.; Zamarrón, P.; López-Vélez, R. Neglected tropical diseases outside the tropics. PLoS Negl. Trop. Dis., 2010, 4, e762.
10. Marreiro Villela, M.; Cortiço Corrêa Rodrigues, V.L.; Casanova, C.; Pinto, J.C. Dias. Analysis on the food source of Panstrongylus megistus (Hemiptera, Reduviidae, Triatominae) and its present importance as a vector for Trypanosoma cruzi, in the State of Minas Gerais. Rev. Soc. Bras. Med. Trop., 2010, 43, 125-128.
11. Cardoso de Paula, M.B.; da Costa, I.N.; de Albuquerque Freitas, P.; Limongi, J.E.; de Albuquerque Pajuaba Neto, A.; de Melo Costa Pinto, R.; Ribeiro Gonçalves, A.L.; Costa-Cruz, J.M. Occurrence of positivity for Trypanosoma cruzi in triatomine from municipalities in Southeastern Brazil, from 2002 to 2004. Rev. Soc. Bras. Med. Trop., 2010, 43, 9-14.
12. Espinoza, B.; Rico, T., Sosa, S.; Oaxaca, E.; Vizcaino-Castillo, A.; Caballero, M.L.; Martínez, I. Mexican Trypanosoma cruzi T. cruzi I strains with different degrees of virulence induce diverse humoral and cellular immune responses in a murine experimental infection model. J. Biomed. Biotechnol., 2010, 2010, 890672.
13. Cerecetto, H.; González, M. Chemotherapy of Chagas' disease: status and new developments. Curr. Top. Med. Chem., 2002, 2, 1187-213.
14. Castro, J.A.; Montalto de Mecca, M.; Bartel, L.C. Toxic side effects of drugs used to treat Chagas' disease (American Trypanosomiasis). Hum. Exp. Toxicol., 2006, 25, 471-479.
15. Jannin, J.; Villa, L. An overview of Chagas disease treatment. Mem. Inst. Oswaldo Cruz, 2007, 102, 95-97.
16. Viotti, R.; Vigliano, C.; Lococo, B.; Alvarez, M.G.; Petti, M.; Bertocchi, G.; Armenti, A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti. Infect. Ther., 2009, 7, 157-163.
17. Marin-Neto, J.A.; Rassi, A.; Avezum, A.; Mattos, A.C.; Rassi, A. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz, 2009, 104, 319-324.
18. Marin-Neto, J.A.; Rassi, A.; Morillo, C.A.; Avezum, A.; Connolly, S.J.; Sosa-Estani, S.; Rosas, F.; Yusuf, S. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J., 2008, 156, 37-43.
19. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi- Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet, 2009, 374, 56-64.
20. Murta, S.M.; Gazzinelli, R.T.; Brener, Z.; Romanha, A.J. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol., 1998, 93, 203-214.
21. Nagel, R. Genotoxicity studies with two antichagasic drugs. Mutat. Res., 1987, 191, 17-20.
22. de Castro, C.R.; Montalto de Mecca, M.; Fanelli, S.L.; de Ferreyra, E.C.; Díaz, E.G.; Castro, J.A. Benznidazole-induced ultrastructural and biochemical alterations in rat esophagus. Toxicol., 2003, 191, 189-198.
23. Bartel, L.C.; Montalto de Mecca, M.; Fanelli, S.L.; Rodriguez de Castro, C.; Diaz, E.G.; Castro, J.A. Early nifurtimox-induced biochemical and ultrastructural alterations in rat heart. Hum. Exp. Toxicol., 2007, 26, 781-788.
24. Cabrera, M.; Lavaggi, M.L.; Hernández, P.; Merlino, A.; Gerpe, A.; Porcal, W.; Boiani, M.; Ferreira, A.; Monge, A.; López de Cerain, A.; González, M.; Cerecetto, H. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5- phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol. Lett., 2009, 190, 140-149.
25. El-Sayed, N.M.; Myler, P.J.; Bartholomeu, D.C.; Nilsson, D.; Aggarwal, G.; Tran, A.N.; Ghedin, E.; Worthey, E.A.; Delcher, A.L.; Blandin, G.; Westenberger, S.J.; Caler, E.; Cerqueira, G.C.; Branche, C.; Haas, B.; Anupama, A.; Arner, E.; Åslund, L.; Attipoe, P.; Bontempi, E.; Bringaud, F.; Burton, P.; Cadag, E.; Campbell, D.A.; Carrington, M.; Crabtree, J.; Darban, H.; da Silveira, J.F.; de Jong, P.; Edwards, K.; Englund, P.T.; Fazelina, G.; Feldblyum, T.; Ferella, M.; Frasch, A.C.; Gull, K.; Horn, D.; Hou, L.; Huang, Y.; Kindlund, E.; Klingbeil, M.; Kluge, S.; Koo, H.; Lacerda, D.; Levin, M.J.; Lorenzi, H.; Louie, T.; Machado, C.R.; McCulloch, R.; McKenna, A.; Mizuno, Y.; Mottram, J.C.; Nelson, S.; Ochaya, S.; Osoegawa, K.; Pai, G.; Parsons, M.; Pentony, M.; Pettersson, U.; Pop, M.; Ramirez, J.L.; Rinta, J.; Robertson, L.; Salzberg, S.L.; Sanchez, D.O.; Seyler, A.; Sharma, R.; Shetty, J.; Simpson, A.J.; Sisk, E.; Tammi, M.T.; Tarleton, R.; Teixeira, S.; Van Aken, S.; Vogt, C.; Ward, P.N.; Wickstead, B.; Wortman, J.; White, O.; Fraser, C.M.; Stuart, K.D.; Andersson, B. Comparative genomics of trypanosomatid parasitic protozoa. Science, 2005, 309, 404-409.
26. Meiering, S.; Inhoff, O.; Mies, J.; Vincek, A.; Garcia, G.; Kramer, B.; Dormeyer, M.; Krauth-Siegel, R.L. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J. Med. Chem., 2005, 48, 4793-4802.
27. Freitas, R.F.; Prokopczyk, I.M.; Zottis, A.; Oliva, G.; Andricopulo, A.D.; Trevisan, M.T.; Vilegas, W.; Silva, M.G.; Montanari, C.A. Discovery of novel Trypanosoma cruzi glyceraldehyde-3- phosphate dehydrogenase inhibitors. Bioorg. Med. Chem., 2009, 17, 2476-2482.
28. Menezes, I.R.; Lopes, J.C.; Montanari, C.A.; Oliva, G.; Pavão, F.; Castilho, M.S.; Vieira, P.C.; Pupo, M.T. 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of Trypanosoma cruzi. J. Comput. Aided Mol. Des., 2003, 17, 277-290.
29. Guido, R.V.; Trossini, G.H.; Castilho, M.S.; Oliva, G.; Ferreira, E.I.; Andricopulo, A.D. Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi. J. Enzyme Inhib. Med. Chem., 2008, 23, 964-973.
30. Trossini, G.H.; Guido, R.V.; Oliva, G.; Ferreira, E.I.; Andricopulo, A.D. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies. J. Mol. Graph. Model, 2009, 28, 3-11.
31. Rivera, G.; Bocanegra-García, V.; Ordaz-Pichardo, C.; Nogueda- Torres, B.; Monge, A. New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives. Curr. Med. Chem., 2009, 16, 3286-3293.
32. Soeiro, M.N.; de Castro, S.L. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin Ther Targets, 2009, 13, 105-121.
33. Urbina, J.A. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop., 2010, 115, 55- 68.
34. Urbina, J.A. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz, 2009, 104, 311-318.
35. McKerrow, J.H.; Doyle, P.S.; Engel, J.C.; Podust, L.M.; Robertson, S.A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I.D.; Brinen, L.S.; Craik, C.S. Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz, 2009, 104, 263-269.
36. Stump, B.; Eberle, C.; Schweizer, W.B.; Marcel Kaiser, M.; Brun, R.; Krauth-Siegel, R.L.; Lentz, D.; Diederich, F. Pentafluorosulfanyl as a novel building block for enzyme inhibitors: Trypanothione reductase inhibition and antiprotozoal activities of diarylamines. ChemBioChem, 2009, 10, 79-83.
37. Eberle, C.; Burkhard, J.A.; Stump, B.; Kaiser, M.; Brun, R.; Krauth-Siegel, R.S.; Diederich, F. Synthesis, inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds. ChemMedChem, 2009, 4, 2034-2044.
38. Jones, D.C.; Ariza, A.; Chow, W.-H.A.; Oza, S.L.; Fairlamb, A.H. Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Mol. Biochem. Parasitol., 2010, 169, 12-19.
39. Cerecetto, H.; González, M. Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of Hit-to-Lead phase. Pharmaceuticals, 2010, 3, 810-838.
40. Bouvier, F.; Rahier, A.; Camara, B. Biogenesis, molecular regulation and function of plant isoprenoids. Prog. Lipid Res., 2005, 44, 357-429.
41. Carrero-Lérida, J.; Pérez-Moreno, G.; Castillo-Acosta, V.M.; Ruiz-Pérez, L.M.; González-Pacanowska, D. Intracellular location of the early steps of the isoprenoid biosynthetic pathway in the trypanosomatids Leishmania major and Trypanosoma brucei. Int. J. Parasitol., 2009, 39, 307-314.
42. Yokoyama, K.; Gillespie, J.R.; Van Voorhis, W.C.; Buckner, F.S.; Gelb, M.H. Protein geranylgeranyltransferase-I of Trypanosoma cruzi Mol. Biochem. Parasitol., 2008, 157, 32-43.
43. Reid, T.S.; Terry, K.L. Casey, P.J.;Beese, L.S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol., 2004, 343, 417-433.
44. Gillespie, J.R.; Yokoyamab, K.; Lu, K.; Eastman, R.T.; Bollinger, J.G.; Van Voorhis, W.C.; Gelb, M.H.; Buckner, F.S. C-Terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Mol. Biochem. Parasitol., 2007, 153, 115-124.
45. Yokoyama, K.; Trobridge, P.; Buckner, F.S.; Van Voorhis, W.C.; Stuart, K.D.; Gelb, M.H. Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics. J. Biol. Chem., 1998, 273, 26497-26505.
46. Buckner, F.S.; Eastman, R.T.; Yokoyama, K.; Gelb, M.H.; Van Voorhis, W.C. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr. Opin. Investig. Drugs, 2005, 6, 791-797.
47. Hucke, O.; Gelb, M.H.; Verlinde, C.L.M.J.; Buckner, F.S. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem., 2005, 48, 5415-5418.
48. Kraus, J.M.; Verlinde, C.L.M.J.; Karimi, M.; Galina I. Lepesheva, Gelb, M.H.; Buckner, F.S. Rational modification of a candidate cancer drug for use against Chagas disease. J. Med. Chem., 2009, 52, 1639-1647.
49. Kraus, J.M.; Tatipaka, H.B.; McGuffin, S.A.; Chennamaneni, N.K.; Karimi, M.; Arif, J.; Verlinde, C.L.M.J.; Buckner, F.S.; Gelb, M.H. Second generation analogues of the cancer drug clinical candidate Tipifarnib for anti-Chagas disease drug discovery. J. Med. Chem., 2010, 53, 3887-3898.
50. Chennamaneni, N.K.; Arif, J.; Buckner, F.S.; Gelb, M.H. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg. Med. Chem. Lett., 2009, 19, 6582-6584.
51. Montalvetti, A., Fernandez, A., Sanders, J.M., Ghosh, S., Van Brussel, E., Oldfield, E., Docampo, R. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J. Biol. Chem., 2003, 278, 17075-17083.
52. Gabelli, S.B.; McLellan, J.S.; Montalvetti, A.; Oldfield, E.; Docampo, R.; Amzel, L.M. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi, implications for drug design. Proteins: Struct. Funct. Bioinformatics, 2006, 62, 80-88.
53. Ferella, M.; Li, Z.-H.; Andersson, B.; Docampo, R. Farnesyl diphosphate synthase localizes to the cytoplasm of Trypanosoma cruzi and T. brucei. Exp. Parasitol., 2008, 119, 308-312.
54. Martin, M.B.; Arnold, W.; Heath, H.T.; Urbina, J.A.; Oldfield, E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun., 1999, 263, 754-758.
55. Bergstrom, J.; Bostedor, D.R.G.; Massarachia, P.J.; Reszka, A.A.; Rodan, G.A. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys., 2000, 373, 231-241.
56. Martin, M.B.; Grimley, J.S.; Lewis, J.C.; Heath, H.T.; Bailey, B.N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J.A.; Moreno, S.N.; Docampo, R.; Croft, S.L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem., 2001, 44, 909-916.
57. Garzoni, L.R.; Caldera, A.; Meirelles, M.N.L.; de Castro, S.L.; Docampo, R.; Meints, G.A.; Oldfield, E.; Urbina, J.A. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Intl. J. Antimicrob. Agents, 2004, 23, 273-285.
58. Garzoni, L.R.; Waghabi, M.C.; Baptista, M.M.; de Castro, S.L.; Meirelles, M.N.L.; Britto, C.C.; Docampo, R.; Oldfield, E.; Urbina, J.A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Intl. J. Antimicrob. Agents, 2004, 23, 286-290.
59. Miranda, K.; de Souza, W.; Plattner, H.; Hentschel, J.; Kawazoe, U.; Fang, J.; Moreno, S.N.J. Acidocalcisomes in apicomplexan parasites. Exp. Parasitol., 2008, 118, 2-9.
60. Szajnman, S.H.; Montalvetti, A.; Wang, Y.; Docampo, R.; Rodriguez, J.B. Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett., 2003, 13, 3231-3235.
61. Szajnman, S.H.; Ravaschino, E.L.; Docampo, R.; Rodriguez, J.B. Synthesis and biological evaluation of 1-amino-1,1- bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett., 2005, 15, 4685-4690.
62. Szajnman, S.H.; García Liñares, G.E.; Li, Z.H.; Jiang, C.; Galizzi, M.; Bontempi, E.J.; Ferella, M.; Moreno, S.N.; Docampo, R.; Rodriguez, J.B. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg. Med. Chem., 2008, 16, 3283-3290.
63. Otero, L.; Vieites, M.; Boiani, L.; Denicola, A.; Rigol, C.; Opazo, L.; Olea-Azar, C.; Maya, J.D.; Morello, A.; Krauth-Siegel, R.L.; Piro, O.E.; Castellano, E.; González, M.; Gambino, D.; Cerecetto, H. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J. Med. Chem., 2006, 49, 3322-3331.
64. Demoro B, Caruso F, Rossi M, Benítez D, Gonzalez M, Cerecetto H, Parajón-Costa B, Castiglioni J, Galizzi M, Docampo R, Otero L, Gambino D. Risedronate metal complexes potentially active against Chagas disease. J. Inorg. Biochem., 2010, 104, 1252-1258.
65. Sandes, J.M.; Borges, A.R.; Junior, C.G.L.; Silva, F.P.L.; Carvalho, G.A.U.; Rocha, G.R.; Vasconcellos, M.L.A.A.; Figueiredo, R.C.B.Q. 3-Hydroxy-2-methylene-3-(4-nitrophenylpropanenitrile): A new highly active compound against epimastigote and trypomastigote form of Trypanosoma cruzi. Bioorg. Chem., 2010, 38, 190-195.
66. Rangel-Aldao, R.; Triana, F.; Fernandez, V.; Comach, G.; Abate, T.; Montoreano, R. Cyclic AMP as an inducer of the cell differentiation of Trypanosoma cruzi. Biochem. Int., 1988, 17, 337-344.
67. Téllez-Iñón, M. T.; Ulloa, R. M.; Torreula, M.; Torres, H. N. Calmodulin and Ca2+-dependent cyclic AMP phosphodiesterase activity in Trypanosoma cruzi. Mol. Biochem. Parasitol., 1985, 17, 143-153.
68. D'Angelo, M.A.; Sanguineti, S.; Reece, J.M.; Birnbaumer, L.; Torres, H.N.; Flawiá, M.M. Identification, characterization and subcellular localization of TcPDE1, a novel cAMP-specific phosphodiesterase from Trypanosoma cruzi. Biochem. J., 2004, 378, 63-72.
69. Kunz, S.; Beavo, J.A.; D'Angelo, M.A.; Flawiá, M.M.; Francis, S.H.; Johner, A.; Laxman, S.; Oberholzer, M.; Rascon, A.; Shakur, Y.; Wentzinger, L.; Zoraghi, R.; Seebeck, T. Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: A unified nomenclature. Mol. Biochem. Parasitol., 2006, 145, 133-135.
70. Alonso, G.D.; Schoijet, A.C.; Torres, H.N.; Flawiá, M.M. TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi. Mol. Biochem. Parasitol., 2006, 145, 40-49.
71. Alonso, G.D.; Schoijet, A.C.; Torres, H.N.; Flawiá, M.M. TcrPDEA1, a cAMP-specific phosphodiesterase with atypical pharmacological properties from Trypanosoma cruzi. Mol. Biochem. Parasitol., 2007, 152, 72-79.
72. King-Keller, S.; Li, M.; Smith, A.; Zheng, S.; Kaur, G.; Yang, X.; Wang, B.; Docampo, R. Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease. Antimicrob. Agents Chemother., 2010, 54, 3738-3745.
73. Irigoín, F.; Cibils, L.; Comini, M.A.; Wilkinson, S.R.; Flohé, L.; Radi, R. Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification. Free Radic. Biol. Med., 2008, 45, 733-742.
74. Oza, S. L.; Tetaud, E.; Ariyanayagam, M. R.; Warnon, S. S.; Fairlamb, A. H. A single enzyme catalyses formation of Trypanothione from glutathione and spermidine in Trypanosoma cruzi. J. Biol. Chem., 2002, 277, 35853-35861.
75. Krauth-Siegel, R. L.; Bauer, H.; Schirmer, R. H. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem. Int. Ed. Engl., 2005, 44, 690-715.
76. Morris, S. M. Recent advances in arginine metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7, 45-51.
77. Fyfe, P. K.; Oza, S. L.; Fairlamb, A. H.; Hunter, W. N. Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities. J. Biol. Chem., 2008, 283, 17672-17680.
78. O'Sullivan, M.C.; Zhou, Q.; Li, Z.; Durham, T.B.; Rattendi, D.; Lane, S.; Bacchi, C.J. Polyamine derivatives as inhibitors of trypanothione reductase and assessment of their trypanocidal activities. Bioorg. Med. Chem., 1997, 5, 2145-2155.
79. Zou, Y.; Wu, Z.; Sirisoma, N.; Woster, P.M.; Casero, R.A.; Weiss, L.M.; Rattendi, D.; Lane, S.; Bacchi, C.J. Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity. Bioorg. Med. Chem. Lett., 2001, 11, 1613-1617.
80. Caterina, M.C.; Perillo, I.A.; Boiani, L.; Pezaroglo, H.; Cerecetto, H.; González, M.; Salerno, A. Imidazolidines as new anti- Trypanosoma cruzi agents: Biological evaluation and structure- activity relationships. Bioorg. Med. Chem., 2008, 16, 2226-2234.
81. Bi, X.; Lopez, C.; Bacchi, C.J.; Rattendi, D.; Woster, P.M. Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity. Bioorg. Med. Chem. Lett., 2006, 16, 3229-3232.
82. Wyllie, S.; Oza, S.L.; Patterson, S.; Spinks, D.; Thompson, S.; Fairlamb, A.H. Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Mol. Microbiol., 2009, 74, 529-540.
83. Carrillo, C.; Serra, M.P.; Pereira, C.A.; Huber, A.; González, N.S.; Algranati, I.D. Heterologous expression of a plant arginine decarboxylase gene in Trypanosoma cruzi. Biochim. Biophys. Acta, 2004, 1674, 223-230.
84. Maldonado, E.; Soriano-García, M.; Moreno, A.; Cabrera, N.; Garza-Ramos, G.; de Gómez-Puyou, M.; Gómez-Puyou, A.; Perez- Montfort, R. Differences in the intersubunit contacts in triosephosphate isomerase from two closely related pathogenic trypanosomes. J. Mol. Biol., 1998, 283, 193-203.
85. Zabori, S.; Rudolph, R.; Jaenicke, R. Folding and association of triose phosphate isomerase from rabbit muscle. Z. Naturforsch., 1980, 35C, 999-1004.
86. Olivares-Illana, V.; Rodríguez-Romero, A.; Becker, I.; Berzunza, M.; García, J.; Pérez-Montfort, R.; Cabrera, N.; López-Calahorra, F.; de Gómez-Puyou, M.T.; Gómez-Puyou, A. Perturbation of the dimer interface of triosephosphate isomerase and its effect on Trypanosoma cruzi. PLoS Negl. Trop. Dis., 2007, 1, e1.
87. Pérez-Montfort, R.; de Gómez-Puyou, M.T.; Gómez-Puyou, A. The interfaces of oligomeric proteins as targets for drug design against enzymes from parasites. Curr. Top. Med. Chem., 2002, 2, 457-470.
88. Gao, X.-G.; Maldonado, E.; Pérez-Montfort, R.; Garza-Ramos, G.; Tuena de Gómez-Puyou, M.; Gómez-Puyou, A.; Rodríguez- Romero, A. Crystal structure of triosephosphate isomerase in hexane. Proc. Natl Acad. Sci. U.S.A., 1999, 96, 100062-100067.
89. Téllez-Valencia, A.; Olivares-Illana, V.; Hernández-Santoyo, A.; Pérez-Montfort, R.; Costas, M.; Rodríguez-Romero, A.; López- Calahorra, F.; Tuena de Go ́mez-Puyou, M.; Go ́mez-Puyou, A. Inactivation of triosephosphate isomerase from Trypanosoma cruzi by an agent that perturbs its dimer interface. J. Mol. Biol., 2004, 341, 1353-1365.
90. Olivares-Illana, V.; Pérez-Montfort, R.; López-Calahorra, F.; Costas, M.; Rodríguez-Romero, A.; Tuena de Gómez-Puyou, M.; Gómez Puyou, A. Structural differences in triosephosphate isomerase from different species and discovery of a multitrypanosomatid inhibitor. Biochemistry, 2006, 45, 2556-2560.
91. Gayosso-De-Lucio, J.; Torres-Valencia, M.; Rojo-Domínguez, A.; Nájera-Peña, H.; Aguirre-López, B.; Salas-Pacheco, J.; Avitia- Domínguez, C.; Téllez-Valencia, A. Selective inactivation of triosephosphate isomerase from Trypanosoma cruzi by brevifolin carboxylate derivatives isolated from Geranium bellum Rose. Bioorg. Med. Chem. Lett., 2009, 19, 5936-5939.
92. Álvarez, G.; Aguirre-López, B.; Varela, J.; Cabrera, M.; Merlino, A.; López, G.V.; Lavaggi, M.L.; Porcal, W.; Di Maio, R.; González, M.; Cerecetto, H.; Cabrera, N.; Pérez-Montfort, R.; Tuena de Gómez-Puyou, M.; Gómez-Puyou, A. Massive screening yields novel and selective T. cruzi triosephosphate isomerase dimerinterface- irreversible inhibitors with anti-trypanosomal activity. Eur. J. Med. Chem., 2010, 45, 5767-5772.
93. Joubert, F.; Neitz, A. W. H.; Louw, A. I. Structure-based inhibitor screening: A family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase. Proteins, 2001, 45, 136-143.
94. Galland, N.; de Walque, S.; Voncken, F.G.J.; Verlinde, C.L.M.J.; Michels, P.A.M. An internal sequence targets Trypanosoma brucei triosephosphate isomerase to glycosomes. Mol. Biochem. Parasitol., 2010, 171, 45-49.
95. Gerez de Burgos, N.M.; Blanco, A.; Segura, E.L. 1978. Formas moleculares de α-hidroxiácido deshidrogenasa en Trypanosoma cruzi. Medicina (Buenos Aires), 1978, 38, 151-154.
96. Elizondo, S.; Chena, M.A.; Rodríguez-Páez, L.; Nogueda, B.; Baeza, I.; Wong, C. Inhibition of Trypanosoma cruzi α- hydroxyacid dehydrogenase-isozyme II by N-isopropyl oxamate and its effect on intact epimastigotes. J. Enzyme Inhib. Med. Chem., 2003, 3, 265-271.
97. Coronel, C.E.; Rovai, L.E.; Gerez de Burgos, N.M.; Burgos, C.; Blanco, A. Properties of α-hydroxyacid dehydrogenase isozymes from Trypanosoma cruzi. Mol. Biochem. Parasitol., 1981, 4, 29-38.
98. Montamat, E.E.; Arauzo, S.S.; Blanco, A. Subcellular localization of leucin amino transferase and α-hydroxyacid dehydrogenase in Trypanosoma cruzi. Mol. Biochem. Parasitol., 1987, 22, 185-193.
99. Montamat, E.E.; Vermouth, N.T.; Blanco, A. Subcellular localization of branched-chain aminoacid amino transferase and lactate dehydrogenase C4 in rat and mouse spermatozoa. Biochem. J., 1988, 255, 1053-1056.
100. Chena, M.A.; Elizondo-Jiménez, S.; Rodríguez-Páez, L.; Nogueda- Torres, B.; Baeza-Ramírez, I.; Wong-Ramírez, C. Trypanosoma cruzi: Inhibition of α-hydroxyacid dehydrogenase isozyme II by Nallyl and N-propyl oxamates and their effects on intact epimastigotes. Mem. Inst. Oswaldo Cruz, 2004, 99, 831-837.
101. Chena, M.A.; Elizondo, S.; Rodríguez-Páez, L.; Nogueda, B.; Baeza, I.; Wong, C. Trypanocidal activity of N-isopropyl oxamate on cultured epimastigotes and murine trypanosomiasis using different Trypanosoma cruzi strains. J. Enzyme Inhib. Med. Chem., 2005, 20, 189-197.
102. Aguirre-Alvarado, C.; Zaragoza-Martínez, F.; Rodríguez-Páez, L.; Nogueda, B.; Baeza, I.; Wong, C. In vitro and in vivo trypanocidal activity of the ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains. J. Enzyme Inhib. Med. Chem., 2007, 22, 227-233.
103. Aguirre-Alvarado, C.; Zaragoza-Martínez, F.; Rodríguez-Páez, L.; Téllez-Rendón, J.L.; Nogueda, B.; Baeza, I.; Wong, C. Trypanocidal activity of the ethyl esters of N-propyl and N-isopropyl oxamates on intracellular amastigotes of Trypanosoma cruzi acute infected mice. J. Enzyme Inhib. Med. Chem., 2010, 25, 111-115.
104. Buschiazzo, A.; Alzari, P.M. Structural insights into sialic acid enzymology. Curr. Op. Chem. Biol., 2008, 12, 565-572.
105. Schenkman, S. Structural and functional properties of Trypanosoma trans-sialidase. Annu. Rev. Microbiol., 1994, 48, 499-523.
106. Yoshida, N.; Dorta, M.L.; Ferreira, A.T.; Oshiro, M.E.M.; Mortara, M.A.; Acosta-Serrano, A.; Favoreto, S. Removal of sialic acid from mucin-like surface molecules of Trypanosoma cruzi metacyclic trypomastigotes enhances parasite-host cell interaction. Mol. Biochem. Parasitol., 1997, 84, 57-67.
107. Pereira-Chioccola, V. L.; Acosta-Serrano, A.; Correia de Almeida, I.; Ferguson, M.A.J.; Souto-Padron, T.; Rodrigues, M.M.; Travassos, L.R.; Schenkman, S. Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-α-galactosyl antibodies. J. Cell Sci., 2000, 113, 1299-1307.
108. Rosenberg, C.S.; Martin, D.L.; Tarleton, R.L. CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J. Immunol., 2010, 185, 560-568.
109. Muiá, R.P.; Yu, H.; Prescher, J.A.; Hellman, U.; Chen, X.; Bertozzi, C.R.; Campetella, O. Identification of glycoproteins targeted by Trypanosoma cruzi trans-sialidase, a virulence factor that disturbs lymphocyte glycosylation. Glycobiology, 2010, 20, 833-842.
110. Neres, J.; Bryce, R.A.; Douglas, K.T. Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease. Drug Discov. Today, 2008, 13, 110-117.
111. Frasch, A.C.C. Functional Diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today, 2000, 16, 282-286.
112. Briones, M.; Egima, C.; Schenkman, S. Trypanosoma cruzi transsialidase gene lacking C-terminal repeats and expressed in epimastigote forms. Mol. Biochem. Parasitol., 1995, 70, 9-17.
113. Tomlinson, S.; Raper, J. Natural human immunity to trypanosomes. Parasitol. Today, 1998, 14, 354-359.
114. Todeschini, A.R.; Girard, M.F.; Wieruszeski, J.M.; Nunes, M.P.; DosReis, G.A.; Mendonça-Previato, L.; Previato, J.O. Transsialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner. J. Biol. Chem., 2002, 277, 45962-45968.
115. Villalta, F.; Smith, C.M.; Ruiz-Ruano, A.; Lima, M.F. A ligand that Trypanosoma cruzi uses to bind to mammalian cells to initiate infection. FEBS Lett., 2001, 505, 383-388.
116. Tribulatti, M.V.; Mucci, J.; Van Rooijen, N.; Leguizamón, M.S.; Campetella, O. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. Infect. Immun., 2005, 73, 201-207.
117. Ferrero-Garcia, M.A.; Trombetta, S.E.; Sanchez, D.O.; Reglero, A.; Frasch, A.C.C.; Parodi, A.J. The action of Trypanosoma cruzi trans-sialidase on glycolipids and glycoproteins. Eur. J. Biochem., 1993, 213, 765-771.
118. Busse, H.; Hakoda, M.; Stanley, M.; Streicher, H. Galactosephosphonates as mimetics of the sialyltransfer by trypanosomal sialidases. J. Carbohydr. Chem., 2007, 26, 159-194.
119. Vandekerckhove, F.; Schenkman, S.; Pontes de Carvalho, L.; Tomlinson, S.; Kiso, M.; Yoshida, M.; Hasegawa, A.; Nussenzweig, V. Substrate specificity of the Trypanosoma cruzi trans-sialidase. Glycobiology, 1992, 2, 541-548.
120. Neres, J.; Brewer M.L.; Ratier, L.; Botti, H.; Buschiazzo, A.; Edwards, P.N.; Mortenson, P.N.; Charlton, M.H.; Alzari, P.M.; Frasch, A.C.; Bryce, R.A.; Douglas, K.T. Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorg. Med. Chem. Lett., 2009, 19, 589-596.
121. Kim, J.H.; Ryu, H.W.; Shim, J.H.; Park, K.H.; Withers, S.G. Development of new and selective Trypanosoma cruzi trans-sialidase inhibitors from sulfonamide chalcones and their derivatives. ChemBioChem, 2009, 10, 2475-2479.
122. Arioka, S.; Sakagami, M.; Uematsu, R.; Yamaguchi, H.; Togame, H.; Takemoto, H.; Hinou, H.; Nishimura, S.-I. Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase. Bioorg. Med. Chem., 2010, 18, 1633-1640.
123. Carvalho, S.T.; Sola-Penna, M.; Oliveira, I.A.; Pita, S.; Gonçalves, A.S.; Neves, B.C.; Sousa, F.R.; Freire-de-Lima, L.; Kurogochi, M.; Hinou, H.; Nishimura, S-I.; Mendonça-Previato, L.; Previato, O., Todeschini, A.R. A new class of mechanism-based inhibitors for Trypanosoma cruzi trans-sialidase and their influence on parasite virulence. Glycobiology, 2010, 20, 1034-1045.
124. Mitchell, F.L.; Miles, S.M.; Neres J.; Bichenkova, E.V.; Bryce, R.A. Tryptophan as a molecular shovel in the glycosyl transfer activity of Trypanosoma cruzi trans-sialidase. Biophys. J., 2010, 98, L38-L40.
125. Jayakumar, P. C.; Musande, V. V.; Shouche, Y. S.; Patole, M. S. The Selenophosphate synthetase gene from Leishmania major. DNA Seq., 2004, 15, 66-70.
126. Lobanov, A. V.; Gromer, S.; Salinas, G.; Gladyshev, V. N. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res., 2006, 34, 4012-4024.
127. Vermelho, A.B.; Giovanni-De-Simone, S.; d'Avila-Levy, C.M.; Santos, A.L.S.; Nogueira de Melo, A.C.; Silva, F.P.; Bon, E.P.; Branquinha, M.H. Trypanosomatidae: peptidases and drugs development. Curr. Enzyme Inhib., 2007, 3, 19-48.
128. Nogueira de Melo, A.C.; de Souza, E.P.; Ramalho Elias, C.G.; Souza dos Santos, A.L.; Branquinha, M.H.; d'Ávila-Levy, C.M: Coelho Garcia dos Reis, F.; Ferreira Rocha Costa, T.; Cabral de Araujo Lima, A.P.; de Souza Pereira, M.C.; Leal Meirelles, M.N.; Vermelho, A.L. Detection of matrix metallopeptidase-9-like proteins in Trypanosoma cruzi. Exp. Parasitol., 2010, 125, 256-263.
129. Barbosa de Melo, L.D.B., Nepomuceno-Silva, J.L.; Sant'Anna, C.; Eisele, N.; Ferraro, R.B.; Meyer-Fernandes, J.R.; de Souza, W.; Cunha-e-Silva, N.L.; Gazos Lopes, U. TcRho1 of Trypanosoma cruzi: role in metacyclogenesis and cellular localization. Biochem. Biophys. Res. Commun., 2004, 323, 1009-1016.
130. Barbosa de Melo, L.D.B.; Eisele, N.; Nepomuceno-Silva, J.L.; Gazos Lopes, U. TcRho1, the Trypanosoma cruzi Rho homologue, regulates cell-adhesion properties: Evidence for a conserved function. Biochem. Biophys. Res. Commun., 2006, 345, 617-622.